LifeWatch AG, a Swiss developer and provider of medical solutions and remote diagnostic monitoring services in the digital health market, has received FDA clearance for its continuous Vital Signs Monitoring Service.
The company’s wireless, patch-based vital signs monitoring system is designed to make vital signs monitoring faster, easier, and more convenient for both patients and medical staff. It allows for early detection of vital sign changes, thereby enabling faster interventions, greater nursing efficiency, and higher patient satisfaction, according to LifeWatch.
The Vital Signs Patch is designed to be an easy-to-use cable-free sensor worn on a patient’s upper chest. It is intended to be used on adult patients in a clinical environment for continuous, noninvasive monitoring of ECG, heart rate, respiration rate, surface temperature, arterial blood oxygen saturation, and body position. Available in two versions (with and without ECG), the Vital Signs Patch is connected with an easy-to-use wireless supporting system, which provides medical information and alerts remotely to medical staff. Although the system will initially be used within medical facilities, future applications will likely include ambulatory settings.
According to LifeWatch, the FDA clearance represents a technological breakthrough for the company, and it is anticipated that the cost benefits of the Vital Signs Patch will allow vital signs monitoring to be utilized for a much broader patient population in the future.
For more information, visit the LifeWatch website.
